Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
3 Healthcare Stocks with Competitive Advantages
23.07.2026 10:22
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 10%, nearly mirroring the S&P 500.
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation
21.07.2026 12:20
Vertex Pharmaceuticals offers affordable growth with strong double-digit earnings and revenue expansion, zero debt, and a P/E below the S&P 500 average—trading at a deep discount to biotech peers.
How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story
20.07.2026 09:09
Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals’ gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a first-in-class gene therapy for very young patients, reinforcing Vertex’s role in genetic medicines beyond its cystic fibrosis core. We’ll examine how broadening...
Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2
20.07.2026 05:07
Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
20.07.2026 00:05
The biotech's diversification efforts continue.
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
16.07.2026 13:06
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
16.07.2026 13:00
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study
16.07.2026 12:00
Technical review to strengthen subsurface model and guide next phase of developmentVANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to provide a corporate update on the ongoing technical study being completed by Lonquist Field Service (Canada), ULC (“Lonquist”) at the Company’s Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoun
The Battle For Sickle Cell
16.07.2026 07:30
The curing sickle cell through gene therapy story is a long way from being written. But itâs for sure that it has not gone like some of its participants have wanted it to. Read more here...
Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada
12.07.2026 03:19
Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...
If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now
10.07.2026 12:30
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?
10.07.2026 12:14
With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.
The Long Climb Back For Ionis Stock
10.07.2026 11:35
A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.
1 Momentum Stock to Research Further and 2 Facing Headwinds
09.07.2026 07:49
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?
09.07.2026 03:39
Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?
08.07.2026 05:11
Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?
08.07.2026 03:34
Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout
08.07.2026 03:09
Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?
Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network
07.07.2026 15:43
All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composit
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
07.07.2026 14:56
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.